| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neovascularization, Pathologic | 30 | 2015 | 353 | 2.980 |
Why?
|
| Wilms Tumor | 18 | 2013 | 38 | 2.890 |
Why?
|
| Specialties, Surgical | 3 | 2023 | 64 | 1.970 |
Why?
|
| Kidney Neoplasms | 18 | 2016 | 621 | 1.930 |
Why?
|
| Endothelial Growth Factors | 14 | 2009 | 55 | 1.570 |
Why?
|
| Lymphokines | 11 | 2003 | 76 | 1.380 |
Why?
|
| Lymphatic Abnormalities | 4 | 2016 | 8 | 1.360 |
Why?
|
| Pediatrics | 4 | 2019 | 344 | 1.330 |
Why?
|
| Vascular Endothelial Growth Factor A | 24 | 2023 | 407 | 1.300 |
Why?
|
| Neuroblastoma | 13 | 2023 | 374 | 1.230 |
Why?
|
| Receptors, Notch | 4 | 2018 | 120 | 1.130 |
Why?
|
| Angiogenesis Inhibitors | 15 | 2012 | 311 | 1.130 |
Why?
|
| Mice, Nude | 31 | 2023 | 790 | 0.970 |
Why?
|
| Mentors | 1 | 2023 | 76 | 0.880 |
Why?
|
| Vascular Endothelial Growth Factors | 13 | 2004 | 56 | 0.750 |
Why?
|
| Child | 20 | 2023 | 6926 | 0.680 |
Why?
|
| Hemolysin Proteins | 1 | 2018 | 34 | 0.670 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2018 | 63 | 0.660 |
Why?
|
| Bacterial Toxins | 1 | 2018 | 111 | 0.630 |
Why?
|
| Neoplasms | 11 | 2013 | 2897 | 0.610 |
Why?
|
| Antibodies, Monoclonal | 10 | 2008 | 1376 | 0.600 |
Why?
|
| Antineoplastic Agents | 6 | 2015 | 2357 | 0.590 |
Why?
|
| Topotecan | 5 | 2004 | 45 | 0.570 |
Why?
|
| Mice | 40 | 2023 | 11352 | 0.560 |
Why?
|
| Physicians | 2 | 2022 | 673 | 0.560 |
Why?
|
| Picibanil | 1 | 2015 | 2 | 0.540 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 263 | 0.540 |
Why?
|
| Lymphangioma | 1 | 2015 | 15 | 0.540 |
Why?
|
| Sclerotherapy | 1 | 2015 | 16 | 0.530 |
Why?
|
| Transitional Care | 1 | 2015 | 18 | 0.520 |
Why?
|
| Sarcoma, Ewing | 3 | 2012 | 42 | 0.520 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2012 | 70 | 0.510 |
Why?
|
| Humans | 68 | 2023 | 86601 | 0.490 |
Why?
|
| Laser Therapy | 1 | 2015 | 142 | 0.470 |
Why?
|
| Hospitals, Pediatric | 1 | 2013 | 106 | 0.440 |
Why?
|
| Esophageal Atresia | 1 | 2012 | 13 | 0.440 |
Why?
|
| Animals | 45 | 2023 | 26581 | 0.440 |
Why?
|
| Transcription Factors | 3 | 2012 | 1565 | 0.430 |
Why?
|
| Transplantation, Heterologous | 8 | 2009 | 363 | 0.430 |
Why?
|
| Bacterial Proteins | 1 | 2018 | 864 | 0.430 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2012 | 8 | 0.430 |
Why?
|
| Esophagus | 1 | 2012 | 102 | 0.420 |
Why?
|
| Receptor, ErbB-2 | 2 | 2003 | 223 | 0.420 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 557 | 0.420 |
Why?
|
| Hemangioma | 3 | 2012 | 60 | 0.420 |
Why?
|
| Tumor Cells, Cultured | 14 | 2008 | 1041 | 0.410 |
Why?
|
| Signal Transduction | 4 | 2018 | 3241 | 0.410 |
Why?
|
| Neoplasm Transplantation | 11 | 2004 | 391 | 0.410 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 99 | 0.400 |
Why?
|
| Neoplasms, Experimental | 4 | 2012 | 269 | 0.390 |
Why?
|
| Neoplasm Metastasis | 3 | 2012 | 1056 | 0.380 |
Why?
|
| Quality of Health Care | 1 | 2013 | 380 | 0.370 |
Why?
|
| Immunohistochemistry | 12 | 2013 | 1753 | 0.350 |
Why?
|
| Angiopoietin-1 | 1 | 2009 | 4 | 0.340 |
Why?
|
| Receptor, TIE-2 | 1 | 2009 | 15 | 0.340 |
Why?
|
| Cell Line, Tumor | 11 | 2020 | 2426 | 0.330 |
Why?
|
| Endothelium, Vascular | 8 | 2009 | 435 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2020 | 458 | 0.320 |
Why?
|
| Microbubbles | 3 | 2020 | 36 | 0.310 |
Why?
|
| Ovarian Diseases | 1 | 2007 | 32 | 0.310 |
Why?
|
| Neoplasm Proteins | 4 | 2004 | 532 | 0.310 |
Why?
|
| Pelvic Neoplasms | 1 | 2007 | 45 | 0.310 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2004 | 70 | 0.300 |
Why?
|
| Brain Ischemia | 1 | 2012 | 398 | 0.300 |
Why?
|
| Female | 35 | 2023 | 44507 | 0.280 |
Why?
|
| Radiation Injuries | 1 | 2007 | 155 | 0.280 |
Why?
|
| Ovary | 1 | 2007 | 257 | 0.280 |
Why?
|
| Propranolol | 2 | 2016 | 45 | 0.260 |
Why?
|
| In Situ Nick-End Labeling | 6 | 2004 | 121 | 0.250 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2008 | 179 | 0.250 |
Why?
|
| In Situ Hybridization | 5 | 2004 | 307 | 0.240 |
Why?
|
| Infant | 9 | 2018 | 3045 | 0.240 |
Why?
|
| Contrast Media | 4 | 2020 | 1077 | 0.240 |
Why?
|
| Apoptosis | 8 | 2023 | 1683 | 0.240 |
Why?
|
| Doxorubicin | 2 | 2023 | 295 | 0.230 |
Why?
|
| Stroke | 1 | 2012 | 965 | 0.220 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2023 | 39 | 0.210 |
Why?
|
| Rhabdoid Tumor | 1 | 2002 | 19 | 0.210 |
Why?
|
| Infant, Newborn | 8 | 2016 | 2378 | 0.210 |
Why?
|
| Perfusion Imaging | 2 | 2020 | 50 | 0.210 |
Why?
|
| Efficiency | 1 | 2022 | 40 | 0.210 |
Why?
|
| Nitric Oxide | 1 | 2023 | 278 | 0.210 |
Why?
|
| Receptor, Notch1 | 2 | 2015 | 85 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2015 | 930 | 0.200 |
Why?
|
| Vascular Neoplasms | 1 | 2001 | 19 | 0.200 |
Why?
|
| Benchmarking | 1 | 2022 | 78 | 0.200 |
Why?
|
| Liver Neoplasms | 4 | 2015 | 735 | 0.200 |
Why?
|
| Vincristine | 1 | 2001 | 111 | 0.200 |
Why?
|
| Mediastinal Neoplasms | 1 | 2001 | 46 | 0.200 |
Why?
|
| Nephrectomy | 2 | 2013 | 294 | 0.190 |
Why?
|
| Guilt | 1 | 2020 | 11 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2012 | 1464 | 0.180 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1920 | 0.180 |
Why?
|
| Social Responsibility | 1 | 2020 | 57 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 879 | 0.180 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 42 | 0.180 |
Why?
|
| Triage | 1 | 2020 | 108 | 0.180 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 4 | 2003 | 44 | 0.180 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 121 | 0.180 |
Why?
|
| DNA-Binding Proteins | 2 | 2018 | 1208 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2002 | 381 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 276 | 0.180 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 116 | 0.170 |
Why?
|
| ADAM10 Protein | 1 | 2018 | 7 | 0.170 |
Why?
|
| Operating Rooms | 1 | 2020 | 126 | 0.170 |
Why?
|
| Infection Control | 1 | 2020 | 115 | 0.170 |
Why?
|
| Diatrizoate Meglumine | 1 | 2018 | 24 | 0.170 |
Why?
|
| Hypoxia | 4 | 2023 | 641 | 0.170 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 696 | 0.170 |
Why?
|
| Tissue Adhesions | 1 | 2018 | 50 | 0.160 |
Why?
|
| Lung Neoplasms | 6 | 2003 | 2261 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2005 | 1313 | 0.160 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2018 | 36 | 0.160 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2018 | 93 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2018 | 54 | 0.160 |
Why?
|
| Intestinal Obstruction | 1 | 2018 | 88 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2004 | 2436 | 0.150 |
Why?
|
| Child, Preschool | 7 | 2018 | 3611 | 0.150 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2009 | 68 | 0.150 |
Why?
|
| Treatment Outcome | 7 | 2016 | 7988 | 0.140 |
Why?
|
| Patient Selection | 1 | 2020 | 685 | 0.140 |
Why?
|
| Cell Division | 5 | 2009 | 696 | 0.140 |
Why?
|
| Surgeons | 1 | 2020 | 238 | 0.140 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 255 | 0.140 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 1 | 2015 | 1 | 0.140 |
Why?
|
| Capillaries | 2 | 2014 | 91 | 0.140 |
Why?
|
| Hemangiosarcoma | 2 | 2006 | 17 | 0.130 |
Why?
|
| Contract Services | 1 | 2015 | 5 | 0.130 |
Why?
|
| Surgicenters | 1 | 2015 | 5 | 0.130 |
Why?
|
| Anastomotic Leak | 1 | 2016 | 96 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 152 | 0.130 |
Why?
|
| Anastomosis, Surgical | 2 | 2016 | 267 | 0.130 |
Why?
|
| Snail Family Transcription Factors | 2 | 2012 | 26 | 0.130 |
Why?
|
| Hepatoblastoma | 3 | 2008 | 12 | 0.130 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2015 | 13 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2012 | 541 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Port-Wine Stain | 1 | 2014 | 2 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1685 | 0.130 |
Why?
|
| Intraoperative Complications | 2 | 2013 | 185 | 0.130 |
Why?
|
| Decision Making | 1 | 2020 | 642 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2016 | 223 | 0.120 |
Why?
|
| Lymphatic Vessels | 1 | 2015 | 68 | 0.120 |
Why?
|
| Arteriovenous Malformations | 1 | 2014 | 41 | 0.120 |
Why?
|
| Microarray Analysis | 2 | 2011 | 96 | 0.120 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2015 | 93 | 0.120 |
Why?
|
| Medical Audit | 1 | 2013 | 41 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 144 | 0.120 |
Why?
|
| Disease Models, Animal | 6 | 2013 | 2232 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2018 | 1197 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2018 | 1196 | 0.120 |
Why?
|
| Trastuzumab | 2 | 2003 | 68 | 0.120 |
Why?
|
| Colon | 1 | 2016 | 496 | 0.120 |
Why?
|
| Appendicitis | 1 | 2014 | 62 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 110 | 0.110 |
Why?
|
| Neoplasm Seeding | 1 | 2013 | 16 | 0.110 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 1999 | 57 | 0.110 |
Why?
|
| Endothelial Cells | 3 | 2023 | 428 | 0.110 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 373 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2013 | 175 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 130 | 0.110 |
Why?
|
| Perfusion | 2 | 2023 | 203 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2018 | 1458 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 174 | 0.110 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 36 | 0.110 |
Why?
|
| Collagen Type XI | 1 | 2011 | 1 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2013 | 312 | 0.110 |
Why?
|
| Tomography, Optical | 1 | 2012 | 9 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 2 | 2004 | 425 | 0.110 |
Why?
|
| Paraffin Embedding | 2 | 2002 | 78 | 0.110 |
Why?
|
| Polyethyleneimine | 1 | 2011 | 7 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 602 | 0.100 |
Why?
|
| Maleimides | 1 | 2011 | 29 | 0.100 |
Why?
|
| Brain Neoplasms | 2 | 2012 | 763 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 552 | 0.100 |
Why?
|
| Genetic Therapy | 2 | 2023 | 342 | 0.100 |
Why?
|
| Phosphorylation | 3 | 2009 | 1106 | 0.100 |
Why?
|
| Cell Hypoxia | 2 | 2009 | 164 | 0.100 |
Why?
|
| Fibrosarcoma | 1 | 1991 | 84 | 0.100 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2012 | 120 | 0.100 |
Why?
|
| Heart Failure | 2 | 2012 | 1203 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2009 | 81 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2012 | 118 | 0.100 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 152 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2014 | 3352 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2004 | 712 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 927 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2009 | 782 | 0.090 |
Why?
|
| Species Specificity | 1 | 2011 | 678 | 0.090 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2009 | 3 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2012 | 139 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2012 | 255 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2004 | 592 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 427 | 0.090 |
Why?
|
| Kidney | 4 | 2016 | 1241 | 0.090 |
Why?
|
| Blood Vessels | 1 | 2009 | 94 | 0.090 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2009 | 27 | 0.090 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 1384 | 0.090 |
Why?
|
| Hamartoma | 1 | 2009 | 31 | 0.090 |
Why?
|
| Adolescent | 5 | 2018 | 8979 | 0.090 |
Why?
|
| Disease Progression | 3 | 2015 | 1531 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 134 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2003 | 1961 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 878 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2015 | 504 | 0.080 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2008 | 54 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1034 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2006 | 27 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2006 | 28 | 0.080 |
Why?
|
| Rhabdomyosarcoma | 1 | 2007 | 40 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 916 | 0.080 |
Why?
|
| Spinal Neoplasms | 1 | 2007 | 50 | 0.080 |
Why?
|
| Sacrum | 1 | 2007 | 40 | 0.080 |
Why?
|
| Vaginal Neoplasms | 1 | 2007 | 83 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2009 | 238 | 0.080 |
Why?
|
| Quality of Life | 1 | 2015 | 1583 | 0.070 |
Why?
|
| Transfection | 1 | 2009 | 896 | 0.070 |
Why?
|
| RNA-Binding Proteins | 2 | 2018 | 246 | 0.070 |
Why?
|
| Lectins | 2 | 2004 | 84 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 33 | 0.070 |
Why?
|
| Sacrococcygeal Region | 1 | 2006 | 9 | 0.070 |
Why?
|
| Ultrasonography | 3 | 2014 | 695 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2018 | 1578 | 0.070 |
Why?
|
| Teratoma | 1 | 2006 | 50 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 85 | 0.070 |
Why?
|
| Chromosomes, Human | 1 | 2005 | 66 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2007 | 237 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2018 | 8475 | 0.070 |
Why?
|
| Bevacizumab | 3 | 2012 | 281 | 0.070 |
Why?
|
| Muscle, Smooth | 2 | 2003 | 354 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2006 | 153 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2008 | 645 | 0.060 |
Why?
|
| United States | 2 | 2015 | 6665 | 0.060 |
Why?
|
| Angiopoietins | 1 | 2004 | 6 | 0.060 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 13 | 0.060 |
Why?
|
| Ephrin-B2 | 1 | 2004 | 3 | 0.060 |
Why?
|
| Polyethylene Glycols | 2 | 2020 | 363 | 0.060 |
Why?
|
| Pregnancy Proteins | 1 | 2004 | 38 | 0.060 |
Why?
|
| Lymphatic System | 1 | 2004 | 52 | 0.060 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 24 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2006 | 300 | 0.060 |
Why?
|
| DNA | 3 | 2023 | 1294 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2600 | 0.060 |
Why?
|
| Thalidomide | 1 | 2003 | 54 | 0.060 |
Why?
|
| Placenta Growth Factor | 1 | 2004 | 70 | 0.060 |
Why?
|
| Fluorescein Angiography | 1 | 2004 | 96 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2023 | 86 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2003 | 42 | 0.060 |
Why?
|
| Models, Animal | 2 | 2001 | 263 | 0.060 |
Why?
|
| Necrosis | 1 | 2003 | 204 | 0.060 |
Why?
|
| Blood Platelets | 1 | 2003 | 149 | 0.060 |
Why?
|
| Heterografts | 1 | 2023 | 98 | 0.050 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2002 | 27 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2003 | 268 | 0.050 |
Why?
|
| Male | 9 | 2018 | 40956 | 0.050 |
Why?
|
| Wound Healing | 2 | 2016 | 344 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2003 | 151 | 0.050 |
Why?
|
| Thrombospondin 1 | 1 | 2002 | 21 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 3092 | 0.050 |
Why?
|
| Survival Rate | 2 | 2008 | 1860 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2015 | 2818 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 102 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 894 | 0.050 |
Why?
|
| Collagen | 2 | 2016 | 269 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2005 | 479 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 2887 | 0.050 |
Why?
|
| Biopsy | 2 | 2016 | 1161 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 235 | 0.050 |
Why?
|
| Time Factors | 3 | 2012 | 5209 | 0.050 |
Why?
|
| Models, Biological | 2 | 2008 | 1749 | 0.050 |
Why?
|
| Ultrasonic Waves | 1 | 2020 | 4 | 0.050 |
Why?
|
| Blood Volume Determination | 1 | 2020 | 14 | 0.050 |
Why?
|
| Photoacoustic Techniques | 1 | 2020 | 8 | 0.050 |
Why?
|
| Gene Expression | 3 | 2009 | 1284 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2013 | 1937 | 0.050 |
Why?
|
| Fibroblasts | 2 | 2015 | 729 | 0.050 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 30 | 0.050 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 32 | 0.050 |
Why?
|
| Reference Values | 1 | 2001 | 674 | 0.050 |
Why?
|
| Actins | 1 | 2003 | 451 | 0.050 |
Why?
|
| Capillary Permeability | 1 | 2020 | 130 | 0.040 |
Why?
|
| Growth Inhibitors | 1 | 1999 | 41 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2015 | 1540 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 683 | 0.040 |
Why?
|
| Anaplasia | 1 | 1998 | 5 | 0.040 |
Why?
|
| Cross Infection | 1 | 2020 | 141 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 178 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2001 | 261 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 1999 | 307 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 751 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 2 | 2013 | 176 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2018 | 172 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1981 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.040 |
Why?
|
| Klippel-Trenaunay-Weber Syndrome | 1 | 2016 | 5 | 0.040 |
Why?
|
| Fetal Therapies | 1 | 2016 | 5 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2015 | 1047 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 1990 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2018 | 237 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2004 | 1052 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2018 | 303 | 0.040 |
Why?
|
| Lens, Crystalline | 1 | 1997 | 69 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2016 | 297 | 0.030 |
Why?
|
| Pregnancy | 2 | 2016 | 2893 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2016 | 104 | 0.030 |
Why?
|
| Collagen Type VII | 1 | 2015 | 3 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 156 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 1801 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 5974 | 0.030 |
Why?
|
| Myeloablative Agonists | 1 | 2015 | 34 | 0.030 |
Why?
|
| Busulfan | 1 | 2015 | 39 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2008 | 322 | 0.030 |
Why?
|
| Cytokines | 1 | 1999 | 776 | 0.030 |
Why?
|
| Alemtuzumab | 1 | 2015 | 83 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2015 | 7 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2015 | 15 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 700 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2015 | 24 | 0.030 |
Why?
|
| Vidarabine | 1 | 2015 | 141 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 2015 | 63 | 0.030 |
Why?
|
| p120 GTPase Activating Protein | 1 | 2014 | 1 | 0.030 |
Why?
|
| Angiography | 2 | 2006 | 208 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2001 | 3636 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 151 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 43 | 0.030 |
Why?
|
| Computer Systems | 1 | 2013 | 79 | 0.030 |
Why?
|
| Mutation | 2 | 2015 | 3967 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2008 | 429 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 458 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 279 | 0.030 |
Why?
|
| Hospitalization | 1 | 2018 | 848 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 996 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 428 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 162 | 0.030 |
Why?
|
| Fetal Diseases | 1 | 2012 | 81 | 0.030 |
Why?
|
| Growth Substances | 1 | 1992 | 80 | 0.030 |
Why?
|
| Tendons | 1 | 1992 | 44 | 0.030 |
Why?
|
| Aging | 1 | 1997 | 691 | 0.030 |
Why?
|
| Plant Lectins | 1 | 2012 | 11 | 0.030 |
Why?
|
| Blood Volume | 1 | 2012 | 51 | 0.030 |
Why?
|
| Oxyhemoglobins | 1 | 2012 | 31 | 0.030 |
Why?
|
| Cardiomegaly | 1 | 2012 | 111 | 0.030 |
Why?
|
| Genes, Regulator | 1 | 2012 | 65 | 0.030 |
Why?
|
| Tendon Injuries | 1 | 1992 | 37 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 364 | 0.030 |
Why?
|
| Sarcoma, Experimental | 1 | 1991 | 53 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 1991 | 37 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1991 | 68 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 481 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 797 | 0.030 |
Why?
|
| Fibroma | 1 | 1991 | 33 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2012 | 179 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1991 | 92 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2015 | 669 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 536 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 2705 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 287 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 678 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 260 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 596 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2012 | 242 | 0.020 |
Why?
|
| Risk Factors | 2 | 2013 | 5416 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 977 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 912 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2009 | 79 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1139 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1185 | 0.020 |
Why?
|
| Receptor, Notch4 | 1 | 2008 | 5 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2008 | 12 | 0.020 |
Why?
|
| Fibroblast Growth Factor 4 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2008 | 46 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 1538 | 0.020 |
Why?
|
| Glucuronidase | 1 | 2008 | 20 | 0.020 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2008 | 21 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 96 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 303 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 115 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 370 | 0.020 |
Why?
|
| Base Sequence | 1 | 1991 | 2330 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 334 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 645 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 270 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2501 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1991 | 3030 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 692 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2006 | 35 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2006 | 44 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 722 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 2261 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2005 | 16 | 0.020 |
Why?
|
| WT1 Proteins | 1 | 2005 | 19 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2005 | 33 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2005 | 129 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2005 | 256 | 0.020 |
Why?
|
| RNA, Untranslated | 1 | 2005 | 63 | 0.020 |
Why?
|
| Skin | 1 | 2008 | 554 | 0.020 |
Why?
|
| Cyclohexanes | 1 | 2004 | 9 | 0.020 |
Why?
|
| Fluorescein | 1 | 2004 | 16 | 0.020 |
Why?
|
| Nitroimidazoles | 1 | 2004 | 8 | 0.020 |
Why?
|
| RNA, Long Noncoding | 1 | 2005 | 102 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 3674 | 0.020 |
Why?
|
| Protein Binding | 1 | 2008 | 1456 | 0.010 |
Why?
|
| Microcirculation | 1 | 2004 | 106 | 0.010 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2004 | 94 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2006 | 233 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 114 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2006 | 351 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 238 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 129 | 0.010 |
Why?
|
| Genome | 1 | 2005 | 372 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2002 | 33 | 0.010 |
Why?
|
| Adult | 3 | 2009 | 25640 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2005 | 628 | 0.010 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 1999 | 23 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1999 | 290 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 1169 | 0.010 |
Why?
|
| Cattle | 1 | 1999 | 376 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 639 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 1999 | 133 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2006 | 1267 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1014 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 1997 | 114 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 2356 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 1997 | 111 | 0.010 |
Why?
|
| Cataract | 1 | 1997 | 86 | 0.010 |
Why?
|
| Light | 1 | 1997 | 289 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1992 | 94 | 0.010 |
Why?
|
| Dogs | 1 | 1992 | 685 | 0.010 |
Why?
|
| Middle Aged | 1 | 1997 | 25017 | 0.000 |
Why?
|